Encouraging results with Roche's novel anti-TIGIT tiragolumab plus Tecentriq

Swiss pharma giant Roche (ROG: SIX) today announced new follow-up efficacy, safety and patient-reported outcomes (PROs) data from the Phase II CITYSCAPE trial, investigating the novel anti-TIGIT cancer immunotherapy tiragolumab plus Tecentriq (atezolizumab) compared with Tecentriq alone as an initial (first-line) treatment for people with PD-L1-positive metastatic non-small cell lung cancer (NSCLC).

The full results are being featured as an oral presentation in the Proffered Paper session 2 (Abstract LBA2) at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2021, taking place December 8-11.

“These encouraging results suggest that combining anti-TIGIT and anti-PD-L1 cancer immunotherapies such as tiragolumab and Tecentriq could potentially represent a novel approach to address unmet needs in cancer,” said Dr Levi Garraway, Roche’s chief medical officer and head of global product development. “With tiragolumab, we have the largest and most advanced anti-TIGIT clinical program, and we look forward to the results of our phase III trials in lung cancer and other challenging tumor types,” he added.

Others working on anti-RIGIT candidates